Cancer Biology

项目摘要(见说明)：癌症生物学计划(CB)的科学目标是了解定义正常和肿瘤细胞生长的分子机制，以便识别和表征参与肿瘤发展、生长和进展的分子、途径和过程。CB是一个新的项目，代表了KUCC的基础科学倡议，并由成员利用分子、生化和基于细胞的方法来统一，这些方法研究癌细胞的异常行为。CB的首要目标是促进合作，促进可以从工作台到床边的基本发现。CB的具体目标是1)促进合作，加强对肿瘤发生、发展和恶性行为背后的细胞、分子和生化机制的发现；以及2)利用基础科学发现激励新癌症疗法的临床前和临床开发。理事会有32个正式成员和11个准成员，代表KUCC的所有机构。即使在KUCC增长的早期阶段，CB已经从癌症相关的同行评审资金中获得了1700万美元，其中190万美元来自NCI，15.1美元来自其他同行评审赞助商。从2006-2010年，成员发表了250篇与癌症相关的同行评审论文，被引用2904次(平均10.8次/发表)，其中7%是方案间相互作用的结果，15%是方案内相互作用的结果。此外，2010年，CB计划成员使用了生物统计与信息学共享资源的10.2%，生物统计与信息学共享资源的7.09%，以及Lead开发与优化共享资源的8.57%。CB由Yvonne wan和Lineng Li共同领导，他们带来了互补的科学专业知识、不断增长的领导经验和多样化的机构代表。他们将与基础科学副主任丹尼·R·韦尔奇密切合作。CB利用了KUMC、KU-Lawrence和斯托尔斯研究所在肝脏、GL、肾脏和造血肿瘤方面的历史优势。最近的招聘扩大了这些倡议，包括乳房、HNSCC和骨肉瘤研究。除了以疾病为基础的主题组织外，CB成员还拥有可组织为四个以学科为基础的主题的专业知识--染色质组织和转录调控、信号通路和发育、癌细胞生物学和干细胞生物学；以及细胞增殖、分化和死亡，

PROJECT SUMMARY (See instructions): The scientific goal of the Cancer Biology program (CB) is to understand the molecular mechanisms that define normal and neoplastic cell growth in order to identify and characterize molecules, pathways and processes that are involved in tumor development, growth and progression. CB is a new program that represents the basic science initiatives of KUCC and is unified by member utilization of molecular, biochemical, and cell-based approaches that study the aberrant behavior of cancer cells. The overarching goal of CB is to catalyze collaborations that promote basic discoveries that can be translated from bench-to-bedside. The Specific Aims of CB are 1) to promote collaboration that enhances discovery of the cellular, molecular and biochemical mechanisms that underlie tumor development, progression and malignant behavior; and 2) to leverage basic science discoveries to inspire pre-clinical and clinical development of novel cancer therapies. CB has 32 full members and 11 associate members, representing all KUCC institutions. Even at this early stage of KUCC growth, CB has garnered $17 million in cancer-related, peer-reviewed funding, of which $1.9 million was from NCI and $15.1 was from other peer-review sponsors. From 2006-2010, members published 250 cancer-relevant, peer-reviewed papers which were cited 2904 times (average 10.8 citations/publication) of which 7% were the result of inter-programmatic interactions and 15% from intra-programmatic interactions. In addition, CB program members accounted for 10.2% of the usage of the Biospecimen Shared Resource, 7.09% of the usage of the Biostatistics & Informatics Shared Resource, and 8.57% of the usage of the Lead Development & Optimization Shared Resource in 2010. CB is jointly led by Yvonne Wan and Linheng Li, who bring complementary scientific expertise, growing leadership experience, and diverse institutional representation. They will work closely with Danny R. Welch, Associate Director for Basic Science. CB has taken advantage of historical strengths at KUMC, KU-Lawrence and the Stowers Institute in liver, Gl, kidney and hematopoietic tumors. Recent recruitments have expanded those initiatives to include breast, HNSCC, and osteosarcoma research. In addition to a disease-based thematic organization, CB members have expertise that can be organized into four discipline-based themes - Chromatin Organization and Transcriptional Regulation, Signaling Pathways and Development, Cancer Cell Biology and Stem Cell Biology; and Cell Proliferation, Differentiation and Death,